Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.
Bacillus Calmette-Guerin (BCG)
Bladder cancer
Immunotherapy
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
09
05
2022
accepted:
15
09
2022
medline:
19
5
2023
pubmed:
21
10
2022
entrez:
20
10
2022
Statut:
ppublish
Résumé
Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.
Identifiants
pubmed: 36266219
pii: S1078-1439(22)00340-4
doi: 10.1016/j.urolonc.2022.09.012
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
BCG Vaccine
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-218Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.